Glaukos Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Glaukos Corp 公司

Glaukos Corporation 是一家眼科药物和医疗技术公司。该公司开发新型无滴疗法，并将相关产品商业化，用于治疗青光眼、角膜疾病和视网膜疾病。其候选产品包括微创青光眼手术产品，该产品涉及插入微型装置，旨在通过恢复青光眼患者的自然房水流出途径来降低眼压 (IOP)，以及基于前房内药物输送技术的程序性药物，旨在通过长时间从眼内输送治疗水平的青光眼药物来降低眼压。其产品包括应用于眼睑的透皮药物，旨在治疗青光眼、干眼症、老花眼和其他眼表疾病和障碍，以及微创、生物可侵蚀的缓释药物输送植入物，以改善患者的视力。

公司简介

公司代码GKOS

公司名称Glaukos Corp

上市日期Jun 25, 2015

CEOMr. Thomas William Burns

员工数量995

证券类型Ordinary Share

年结日Jun 25

公司地址1 Glaukos Way

城市ALISO VIEJO

上市交易所NYSE Consolidated

国家United States of America

邮编92656

电话19493679600

网址https://www.glaukos.com

公司代码GKOS

上市日期Jun 25, 2015

CEOMr. Thomas William Burns

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.50M

-0.34%

Mr. David F. Hoffmeister

Independent Director

69.52K

+56.16%

Mr. Mark J. Foley

Lead Independent Director

56.36K

+3.89%

Ms. Aimee S. Weisner, J.D.

Independent Director

49.23K

+4.47%

Mr. Marc A. Stapley

Independent Director

36.18K

+6.19%

Dr. Tomas Navratil

Chief Development Officer

32.88K

-13.52%

Dr. Leana S. Wen, M.D.

Independent Director

--

Dr. Gilbert H. (Gil) Kliman, M.D.

Independent Director

--

Ms. Denice M. Torres, J.D.

Independent Director

--

Mr. Joseph E. Gilliam

President, Chief Operating Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.50M

-0.34%

Mr. David F. Hoffmeister

Independent Director

69.52K

+56.16%

Mr. Mark J. Foley

Lead Independent Director

56.36K

+3.89%

Ms. Aimee S. Weisner, J.D.

Independent Director

49.23K

+4.47%

Mr. Marc A. Stapley

Independent Director

36.18K

+6.19%

Dr. Tomas Navratil

Chief Development Officer

32.88K

-13.52%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Glaucoma

88.14M

82.63%

Corneal Health

18.53M

17.37%

地区USD

名称

营收

占比

United States

75.07M

70.38%

International

31.59M

29.62%

业务

地区

业务USD

名称

营收

占比

Glaucoma

88.14M

82.63%

Corneal Health

18.53M

17.37%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.77%

The Vanguard Group, Inc.

10.63%

Fidelity Management & Research Company LLC

9.14%

Wellington Management Company, LLP

5.66%

State Street Global Advisors (US)

3.64%

其他

57.16%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.77%

The Vanguard Group, Inc.

10.63%

Fidelity Management & Research Company LLC

9.14%

Wellington Management Company, LLP

5.66%

State Street Global Advisors (US)

3.64%

其他

57.16%

股东类型

持股股东

占比

Investment Advisor

56.50%

Investment Advisor/Hedge Fund

34.87%

Hedge Fund

9.09%

Individual Investor

3.31%

Pension Fund

2.57%

Research Firm

1.75%

Sovereign Wealth Fund

1.40%

Bank and Trust

1.12%

Family Office

0.05%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

638

61.06M

106.48%

+15.37K

2025Q1

643

60.20M

105.40%

-1.30M

2024Q4

610

59.75M

105.65%

+533.86K

2024Q3

567

57.47M

104.31%

-894.95K

2024Q2

545

56.86M

103.79%

-713.22K

2024Q1

509

54.47M

110.12%

-1.91M

2023Q4

480

53.71M

109.34%

-1.79M

2023Q3

475

52.90M

108.58%

-1.85M

2023Q2

486

51.69M

106.83%

-2.99M

2023Q1

490

50.54M

105.57%

-3.20M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

7.64M

13.38%

-218.59K

-2.78%

Mar 31, 2025

The Vanguard Group, Inc.

5.95M

10.42%

-9.86K

-0.17%

Mar 31, 2025

Fidelity Management & Research Company LLC

5.57M

9.74%

+417.67K

+8.11%

Mar 31, 2025

Wellington Management Company, LLP

2.29M

4.01%

+131.25K

+6.08%

Mar 31, 2025

State Street Global Advisors (US)

1.98M

3.47%

-79.01K

-3.83%

Mar 31, 2025

PRIMECAP Management Company

1.22M

2.13%

+4.15K

+0.34%

Mar 31, 2025

Burns (Thomas William)

1.50M

2.62%

-5.16K

-0.34%

May 27, 2025

Geode Capital Management, L.L.C.

1.22M

2.13%

+17.85K

+1.49%

Mar 31, 2025

AllianceBernstein L.P.

1.28M

2.24%

+461.39K

+56.53%

Mar 31, 2025

Westfield Capital Management Company, L.P.

1.08M

1.9%

+277.03K

+34.32%

Mar 31, 2025

持股ETF

更新时间: 8月6日周三

机构名称

占比

Invesco S&P SmallCap Health Care ETF

3.32%

Alger Weatherbie Enduring Growth ETF

2.15%

SPDR S&P Health Care Equipment ETF

1.9%

ROBO Global Healthcare Technology & Innovation ETF

1.59%

Invesco S&P SmallCap Momentum ETF

1.42%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.86%

SPDR S&P 600 Small Cap Growth ETF

0.86%

OneAscent Small Cap Core ETF

0.68%

iShares U.S. Medical Devices ETF

0.67%

iShares S&P Small-Cap 600 Growth ETF

0.67%

Invesco S&P SmallCap Health Care ETF

占比3.32%

Alger Weatherbie Enduring Growth ETF

占比2.15%

SPDR S&P Health Care Equipment ETF

占比1.9%

ROBO Global Healthcare Technology & Innovation ETF

占比1.59%

Invesco S&P SmallCap Momentum ETF

占比1.42%

Vanguard S&P Small-Cap 600 Growth Index Fund

占比0.86%

SPDR S&P 600 Small Cap Growth ETF

占比0.86%

OneAscent Small Cap Core ETF

占比0.68%

iShares U.S. Medical Devices ETF

占比0.67%

iShares S&P Small-Cap 600 Growth ETF

占比0.67%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Glaukos Corp

83.470USD

Glaukos Corp

83.470

概览

公司

财务

分析